Morgan Stanley has upgraded Johnson & Johnson to Overweight, citing the strong commercial momentum of its new product pipeline. The firm raised its price target to $262 from $200, anticipating earnings beats driven by multiple product cycles. J&J's stock has already gained 43% last year, outperforming the S&P 500, with reduced uncertainty in the biopharma sector.

The upgrade reflects confidence in J&J's robust new product launches, including drugs like Tremfya and Icotyde in immunology and Tecvayli in multiple myeloma. Morgan Stanley projects compound annual growth of approximately 5.5% for revenue and 12% for earnings between 2026 and 2030. This growth places J&J in a higher-growth category within the biopharma industry.

J&J is trading at around 19x and 17x Morgan Stanley’s 2026 and 2027 earnings estimates, respectively, representing a discount to the broader market. The firm expects that new product launches will offset patent expirations in the coming years. Investors should watch how these new drugs perform in the market and contribute to J&J's financial results.

The analysts' positive outlook hinges on the success of J&J's innovative drugs. These include Tremfya and Icotyde in immunology, Tecvayli and Carvykti in multiple myeloma, which should lift annual revenue by $3 billion to $7 billion. This is a positive signal for investors as the company navigates the ever-changing pharmaceutical sector.